Ge Long Hui·2025-08-26 09:35Core Viewpoint - Shandong Xinhua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the drug registration certificate of Sacubitril/Valsartan tablets, indicating a significant advancement in its product portfolio for treating heart failure and hypertension [1] Group 1: Product Approval - The company has been granted a drug registration certificate for Sacubitril/Valsartan tablets, which are indicated for adult patients with heart failure with reduced ejection fraction (NYHA class II-IV, LVEF ≤ 40%) [1] - This medication aims to reduce the risk of cardiovascular death and hospitalization due to heart failure [1] - Sacubitril/Valsartan tablets can replace ACE inhibitors or ARBs and can be used in combination with other heart failure treatments [1] Group 2: Therapeutic Applications - In addition to heart failure, Sacubitril/Valsartan tablets are also indicated for the treatment of primary hypertension [1]